Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Open accessThe DOI matches its Crossref record; 170 of the 172 references it cites were found in a registry or an index.
Abstract
Over the past 30 years, the majority of (pre)clinical efforts to find an effective therapy for Alzheimer’s disease (AD) focused on clearing the β-amyloid peptide (Aβ) from the brain since, according to the amyloid cascade hypothesis, the peptide was (and it is still considered by many) the pathogenic determinant of this neurodegenerative disorder. However, as reviewed in this article, results from the numerous clinical trials that have tested anti-Aβ therapies to date indicate that this peptide plays a minor role in the pathogenesis of AD. Indeed, even Aducanumab and Lecanemab, the two antibodies recently approved by the FDA for AD therapy, as well as Donanemab showed limited efficacy on cognitive parameters in phase III clinical trials, despite their capability of markedly lowering Aβ brain load. Furthermore, preclinical evidence demonstrates that Aβ possesses several physiological functions, including memory formation, suggesting that AD may in part be due to a loss of function of this peptide. Finally, it is generally accepted that AD could be the result of many molecular dysfunctions, and therefore, if we keep chasing only Aβ, it means that we cannot see the forest for the trees.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings suggest that Aβ deposition or plaque formation might not be the actual cause of the disease, but rather a result or secondary factor of the pathological process.77,148”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [77]
Experimental — accuracy not yet measuredIn the citing paper
“According to the amyloid cascade hypothesis, tau protein tangles and neuroinflammation are brought on by Aβ aggregation, which in turn leads to neuronal death and cognitive decline [90,91,92].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“In 1992, this view culminated in the formulation of the original version of the amyloid cascade hypothesis (ACH) by Hardy and Higgins [12].”
BackgroundThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 2×
“However, Aβ accumulation seems to occur through different mechanisms, being mainly due to increased production or decreased clearance in the familial and sporadic forms, respectively [27].”
BackgroundLecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · cited 1×
“A total of 799 patients met the eligibility criteria for prodromal AD according to the International Working Group criteria [63], showing biomarker evidence of amyloid pathology (CSF Aβ42 levels ≤ 600 ng/L) and absence of dementia diagnosis assessed with MMSE, CDR, CDR-SB, and FCSRT (Free and Cued Selective Reminding…”
MethodTriple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126 · cited 8×
“On the contrary, what is not controversial is the observation that there is no widespread frank neuronal death, and no neurofibrillary tangles (NTFs) are present in the vast majority of transgenic murine models of FAD.”
BackgroundInfluentialVassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“Aducanumab is a human monoclonal antibody selectively targeting different forms of aggregated Aβ, which, like gantenerumab, shows preferred binding to fibrils over protofibrils and has low affinity for Aβ monomers [61,82].”
Background
Research works printed but not linked: 7
- Gantenerumab Mystery: How Did It Lose Potency in Phase 3? Available online: https://www.alzforum.org/news/conference- coverage/gantenerumab-mystery-how-did-it-lose-potency-phase-3 (accessed on 25 August 2023).
- Alzforum.Org API ADAD Columbia Trial Reported Results. Available online: https://www.alzforum.org/news/conference- coverage/crenezumab-secondaries-negative-gantenerumab-ole-hints-efficacy (accessed on 29 August 2023).
- Brenman, 2023, Lecanemab in Early Alzheimer’s Disease, N. Engl. J. Med., 388, 1631
- Valenzuela, 2023, Lecanemab in Early Alzheimer’s Disease, N. Engl. J. Med., 388, 1630, 10.1056/NEJMc2301380 · DOI · Paper page
- Sabbagh, 2023, Response: Lecanemab in Early Alzheimer’s Disease, N. Engl. J. Med., 388, 1631
- Zeng, 2023, Lecanemab in Early Alzheimer’s Disease, N. Engl. J. Med., 388, 1630, 10.1056/NEJMc2301380 · DOI · Paper page
- CrossRef] [PubMed] 122.
Cited by
Items 101–106 of 106
Yadav, P., Mishra, D., & Singh, R. (2026) · Drug Development Research · doi:10.1002/ddr.70381
Advances in the treatment of Alzheimer's disease upon nanozymes
Yan, Y., Liu, Q., Huo, Y., Wang, H., Cheng, Y., Qiao, H., & Zhang, R. (2026) · Nano Today · doi:10.1016/j.nantod.2026.103197
Yuqi, L., & Gu, J. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1925934
“Recent studies have identified numerous genetic risk loci associated with SAD, involving pathways related to immune response, lipid metabolism, amyloid-β (A β ) plaques, neurofibrillary tangles (NFTs), and endocytosis; however, many risk loci remain undiscovered (Fedele, 2023; Kepp et al., 2023).”
Computational Analysis of Serpentine and its structural stereoisomers as promising BACE 1 Inhibitors
Srivastava, S., & Kumar, P. (2026) · International Conference on Innovative Sustainable Computational Technologies (CISCT) · doi:10.1109/cisct69589.2026.11726910
“Whereas sporadic AD usually occurred after 65yrs and is linked by the combination of environmental factors, genetic risks and various other factors [13].”
Alinaghipour, A. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261485286
Mazumder, A., Mishra, R., Varshney, H., Gupta, P. K., Pathak, A., Salma, A., Hussain, S. A., Siva Devi, S., & Sudha, M. (2026) · Oriental Journal Of Chemistry · doi:10.13005/ojc/420523
Metadata
- Authors
- Fedele, E.
- Affiliations
- Ospedale Policlinico San Martino (IT)
- Corresponding author
- Fedele, Ernesto
- ORCID
- Fedele, Ernesto
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-09-24
- Volume
- 24
- Issue
- 19
- Pages
- 14499
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10578107
- OpenAlex
- W4386996842
- Cited by
- 102
- References
- 172
- Citations by year
- 2026: 28 · 2025: 47 · 2024: 26 · 2023: 1
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- Funders
- The University of Genoa
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, anti-amyloid therapy, amyloid hypothesis, amyloid-beta, aducanumab, lecanemab, donanemab, memory formation, amyloid pathogenesis, clinical trial efficacy
- MeSH terms
- Alzheimer Disease, Amyloid, Brain, Humans, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.